66582-32-9

Basic information

• Product Name: 3-(benzyloxy)-2,2-diMethylpropan-1-ol
• Synonyms: 3-(benzyloxy)-2,2-diMethylpropan-1-ol;3-(Benzyloxy)-2,2-diMethyl-1-propanol
• CAS NO: 66582-32-9
• Molecular Formula: C₁₂H₁₈O₂
• Molecular Weight: 194.27012
• Mol File: 66582-32-9.mol
• Article Data: 41

Chemical Properties

• Boiling Point: 120 °C(Press: 0.1 Torr)
• Appearance: /
• Density: 1.010±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DCM, Ethyl Acetate, Methanol
• PKA: 14.90±0.10(Predicted)
• CAS DataBase Reference: 3-(benzyloxy)-2,2-diMethylpropan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(benzyloxy)-2,2-diMethylpropan-1-ol(66582-32-9)
• EPA Substance Registry System: 3-(benzyloxy)-2,2-diMethylpropan-1-ol(66582-32-9)

Safety Data

• Hazardous Substances Data: 66582-32-9(Hazardous Substances Data)

Usage

Description

3-(Benzyloxy)-2,2-dimethylpropan-1-ol is an organic compound characterized by its benzyloxy and dimethylpropan-1-ol functional groups. It is a colorless liquid with a distinct aromatic odor and is known for its reactivity and stability in various chemical reactions.

Uses

Used in Chemical Synthesis:
3-(Benzyloxy)-2,2-dimethylpropan-1-ol is used as a protected intermediate for NPG Glycol (N897000), which is a key component in the synthesis of various organic compounds. Its protective nature allows for selective reactions, making it a valuable asset in the field of organic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-(Benzyloxy)-2,2-dimethylpropan-1-ol is used as a building block for the synthesis of complex drug molecules. Its unique structure and reactivity enable the creation of novel compounds with potential therapeutic applications.
Used in Tetraphenylporphyrin Synthesis:
3-(Benzyloxy)-2,2-dimethylpropan-1-ol is also utilized in the synthesis of tetraphenylporphyrins, which are important compounds in the field of materials science and have applications in areas such as solar energy conversion, catalysis, and molecular electronics.

Upstream product

• 100-44-7 benzyl chloride 
• 126-30-7 2,2-Dimethyl-1,3-propanediol 
• 776-88-5 5,5-dimethyl-2-phenyl-[1,3]dioxane 
• 100-39-0 benzyl bromide 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 100-52-7 benzaldehyde 
• 96556-40-0 methyl-3-(benzyloxy)-2.2-dimethylpropionate 
• 14002-80-3 Methyl 2,2-dimethyl-3-hydroxypropionate 
• 38216-93-2 3-benzyloxypivalic aldehyde 
• 116945-47-2 3-methyl-3-(3-phenyl-2-oxapropyl)oxetane 
• 774-48-1 (diethoxymethyl)benzene 

Downstream Products

• 38216-93-2 3-benzyloxypivalic aldehyde 
• 122166-76-1 3-(benzyloxy)-2,2-dimethylpropyl methanesulfonate 
• 957791-54-7 (E)-N-(3-(benzyloxy)-2,2-dimethylpropylidene)-4-methoxybenzenamine 
• 957791-46-7 (3R,4S)-3-acetoxy-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 865154-57-0 (3S,4R)-4-(2-benzyloxy-1,1-dimethylethyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one 
• 865154-54-7 (3R,4S)-3-hydroxy-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-44-5 (3R,4S)-3-hydroxy-4-(1,1-dimethyl-2-hydroxyethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-56-9 (4R)-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidine-2,3-dione 
• 957791-68-3 (3R,4S)-4-(2-benzyloxy-1,1-dimethylethyl)-3-(tert-butyldimethylsilanyloxy)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-70-7 (3R,4S)-3-(tert-butyldimethylsilanyloxy)-4-(1,1-dimethyl-2-hydroxy-ethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-72-9 (3R,4S)-3-(tert-butyldimethylsilanyloxy)-4-(1-formyl-1,1-dimethylmethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-74-1 (3R,4S)-3-(tert-butyldimethylsilanyloxy)-4-(2-(tert-butyldimethylsilanyloxy)-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 262375-60-0 (E)-7-Benzyloxy-6,6-dimethyl-hept-4-en-3-one 
• 262375-78-0 7-benzyloxy-5-hydroxy-6,6-dimethyl-heptan-3-one 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF TEZACAFTOR INTERMEDIATE

The present invention relates to an improved process for the preparation of tezacaftor intermediate compound of formula II. More particularly, the present invention relates to an improved, commercially viable process for the preparation of tezacaftor inte

Stereoselective Synthesis of γ-Butyrolactones Subunit of Polycavernoside A

An efficient and versatile linear synthesis of γ-butyrolactone subunit of polycavernolide A has been reported in 14.2% overall yield with 10 linear steps by employing Sharpless asymmetric epoxidation, ring-closing metathesis, and diastereoface selective h

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).